Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multicenter, Phase 2a, randomized, double-blind, placebo (vehicle)-controlled, parallel-group, dose-finding study designed to evaluate the efficacy, safety and tolerability of NRD135S.E1 in adult patients with diabetes mellitus type 1 or 2 with neuropathic pain. Potential study patients will sign informed consent prior to undergoing any study-related procedure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)

NCT00837941

Painful Diabetic Neuropathy

WITHDRAWN PHASE2

A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain

NCT01820715

Diabetic Neuropathy

COMPLETED PHASE1

Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy

NCT03755934

Painful Diabetic Neuropathy

TERMINATED PHASE2

Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients

NCT01363284

Diabetes Painful Neuropathy

COMPLETED NA

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy

NCT01893125

Diabetic Peripheral Neuropathy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Following screening, eligible patients will be enrolled and go through a week of washout of analgesic treatment. Patients who are still eligible following the washout will be randomized to one of four treatment groups: NRD135S.E1 at 10, 40, or 150 mg per day or placebo (vehicle).

All four treatment groups will start study treatment with 1 week of single blind placebo (baseline week) followed by 3 weeks of the allocated double blind treatment (Weeks 1, 2, and 3). All patients will be followed for 30 days after the last study drug administration. The total study duration per patient is 9 to10 weeks.

Visit schedule: Screening (Days minus 14 to minus 8, Visit 1). Washout visit (Day minus 7, Visit 2). Randomization and start of placebo treatment (Day 1, Visit 3). Double blind treatment visits on Days 8 (Visit 4), 15 (Visit 5) and 29 (Visit 6). Follow up visit by telephone (Day 59, Visit 7).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NRD135S.E1 A

A = 10 mg NRD135S.E1 once daily PO for 21 days

Group Type EXPERIMENTAL

NRD135S.E1

Intervention Type DRUG

A small chemical entity for treatment of neuropathic pain NRD135S.E1

NRD135S.E1 B

B = 40 mg NRD135S.E1 once daily PO for 21 days

Group Type EXPERIMENTAL

NRD135S.E1

Intervention Type DRUG

A small chemical entity for treatment of neuropathic pain NRD135S.E1

NRD135S.E1 C

C = 150 mg NRD135S.E1 once daily PO for 21 days

Group Type EXPERIMENTAL

NRD135S.E1

Intervention Type DRUG

A small chemical entity for treatment of neuropathic pain NRD135S.E1

Placebo to match NRD135S.E1 D

D = Placebo once daily PO for 21 days

Group Type PLACEBO_COMPARATOR

Placebo to match NRD135S.E1

Intervention Type DRUG

Placebo capsule to match NRD135S.E1 capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NRD135S.E1

A small chemical entity for treatment of neuropathic pain NRD135S.E1

Intervention Type DRUG

Placebo to match NRD135S.E1

Placebo capsule to match NRD135S.E1 capsules

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

E1 Placebo for E1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. -Males agree to use condoms throughout treatment and follow up study periods.

* Females must not be of childbearing potential as evidenced by at least one of the following:

≥ 62 years old and amenorrheic for ≥ 1 year
* Amenorrheic ≥ 12 consecutive months and a documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL
* Irregular menstrual periods and a documented FSH level \> 35 mIU/mL
* On hormone replacement therapy and prior clinical evidence of menopause based on any of the criteria above
* Surgically sterile
2. Known stable diabetes mellitus for the last 3 months. (No oral hypoglycemic medications change allowed. Maximum insulin change allowed is ± 20%).
3. Evidence of peripheral neuropathy associated with diabetes mellitus diagnosed by DN4 criteria.
4. Presence of ongoing pain due to DPN for at least 3 months.
5. Mean DPN pain intensity of 4 to 9 on the NPS at screening.
6. HbA1c ≤ 9% of total hemoglobin at screening.
7. Willing to stop pain medications for DPN (except for limited use of paracetamol).
8. Signed written informed consent.

* Subjects must have signed and dated an Institutional Review Board / Independent Ethics Committee approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.
* Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.

Exclusion Criteria

1. Female of childbearing potential.
2. Neurologic disorders unrelated to DPN that may interfere with the assessment of DPN.
3. Known allergy or intolerance to paracetamol.
4. Evidence of non-DPN polyneuropathy.
5. The presence of severe pain associated with conditions other than DPN (e.g., peripheral vascular disease, phantom pain, etc.) that could confound the self-evaluation of pain due to DPN.
6. Any anti-epileptic or anti-depressive treatment. Amityptiline (Elatrol/Elatrolet) or duloxetine (Cymbalta) are permitted at screening but not later.
7. Constant use of non-steroidal anti-inflammatory drugs or opiates that cannot be withdrawn during the washout period and the whole study duration.
8. Participation in another clinical trial in the last 3 months.
9. Poor compliance with prescribed medication or alcohol or drug abuse within 2 years before screening.
10. Hypersensitivity to paracetamol or any of the inactive ingredients in NRD135S.E1 capsules.
11. Any serious medical condition, including the presence of laboratory abnormalities, that places the patient at an unacceptable risk if he or she participates in this study or confounds the ability to interpret data from the study.
12. Patients with any hematological disorder.
13. Prisoners or subjects who are involuntarily incarcerated.
14. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness.
15. Patients whose judgment has been impaired by their physical ir mental condition

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No